EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China

50Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: EGFR-tyrosine kinase inhibitors play an important role in the treatment of advanced non-small cell lung cancer (NSCLC). EGFR mutations in advanced NSCLC occur in approximately 35% of Asian patients and 60% of patients with adenocarcinoma. However, the frequency and type of EGFR mutations in early-stage lung adenocarcinoma remain unclear. Methods: We retrospectively collected data on patients diagnosed with lung adenocarcinoma tested for EGFR mutation. Early stage was defined as pathological stage IA–IIIA after radical lung cancer surgery, and advanced stage was defined as clinical stage IIIB without the opportunity for curative treatment or stage IV according to the American Joint Committee on Cancer Staging Manual, 7th edition. Results: A total of 1699 patients were enrolled in this study from May 2014 to May 2016; 750 were assigned to the early-stage and 949 to the advanced-stage group. Baseline characteristics of the two groups were balanced, except that there were more smokers in the advanced-stage group (P < 0.001). The total EGFR mutation rate in the early-stage group was similar to that in the advanced-stage group (53.6% vs. 51.4%, respectively; P = 0.379). There was no significant difference in EGFR mutation type between the two groups. In subgroup analysis of smoking history, there was no difference in EGFR mutation frequency or type between the early-stage and advanced-stage groups. Conclusion: Early-stage and advanced-stage groups exhibited the same EGFR mutation frequencies and types.

References Powered by Scopus

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib

10534Citations
N/AReaders
Get full text

EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

8911Citations
N/AReaders
Get full text

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7614Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

112Citations
N/AReaders
Get full text

Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

51Citations
N/AReaders
Get full text

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC)

43Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pi, C., Xu, C. R., Zhang, M. feng, Peng, X. xiao, Wei, X. wu, Gao, X., … Zhou, Q. (2018). EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thoracic Cancer, 9(7), 814–819. https://doi.org/10.1111/1759-7714.12651

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

53%

Lecturer / Post doc 3

18%

Researcher 3

18%

Professor / Associate Prof. 2

12%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

40%

Pharmacology, Toxicology and Pharmaceut... 6

30%

Biochemistry, Genetics and Molecular Bi... 5

25%

Computer Science 1

5%

Save time finding and organizing research with Mendeley

Sign up for free
0